Loading...
Market
Primary barrier to Lenacapavir distribution by end of 2025?
2
Resolution / Starting Odds
Logistical challenges • 25%
Regulatory hurdles • 25%
Funding issues • 25%
Other • 25%
Reports from Global Fund, PEPFAR, and health organizations, news articles
Story
Global Fund and PEPFAR to Distribute Lenacapavir, 100% Success Rate, to 2 Million People by 2026
Dec 17, 2024, 03:09 PM
A new long-acting preventive drug for HIV, known as Lenacapavir, is set to be distributed in the world's poorest countries by late 2025 or early 2026. This initiative is part of a coordinated effort by the Global Fund and PEPFAR, aiming to reach 2 million people with the drug, which has shown 100% success in trials. Health officials believe that this drug could significantly reduce global HIV infections and accelerate the fight against the virus by 2030.
View original story
Similar markets
Cost • 25%
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Cost • 25%
Regulatory approvals • 25%
Manufacturing capacity • 25%
Public awareness • 25%
Cost of the drug • 25%
Distribution and accessibility issues • 25%
Lack of awareness and education • 25%
Regulatory hurdles • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
